Allergy or hypersensitivity to components of the cobimetinib formulations
The subject has a history of allergy or intolerance to flucytosine
No known allergy to aspirin
Patients must not have any known allergy or reaction to any component of the durvalumab (MEDI4736) and/or tremelimumab formulation
Patients must not have prior history of allergy or known hypersensitivity to nivolumab or ipilimumab
No known allergy to 5-fluorouracil, oxaliplatin, or leucovorin
Known allergy to boron or excipients in the formulation
Patients with known allergy to mitoxantrone, cytarabine, or both etoposide and etoposide phosphate (Etopophos)
Patients with a known or documented anaphylactic reaction or allergy to any of chemotherapy agents used in this protocol, or to antiemetics appropriate for administration in conjunction with protocol-directed therapy
Known allergy to any of the study agents
Allergy or hypersensitivity to cemiplimab or to any of its excipients;
Known allergy, hypersensitivity or contraindication to components of the FPA144 formulation including polysorbate or to platinum-containing medications, 5-FU, or leucovorin
Known allergy or hypersensitivity to any of the study drugs or their excipients.
History of allergy or hypersensitivity to any study drugs or their excipients
Allergy or hypersensitivity to components of the KO-947 formulation, e.g. dextrose, hydroxypropyl beta cyclodextrin, acetic acid, sodium acetate and water for injection.
Known allergy to both xanthine oxidase inhibitors and rasburicase
A known history of allergy to docetaxel, Cremophor or polysorbate 80 (Tween 80)
History of allergy to study drug components
Known allergy to eggs, gentamicin, or platinum containing compounds
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known allergy to enadenotucirev, nivolumab or their excipients
Known allergy, hypersensitivity, or contraindication to paclitaxel, docetaxel, or irinotecan or any components used in their preparation
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Allergy to iodine or gadolinium contrast that cannot be safely controlled with premedication
Patients who have a known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent are not eligible
Known history of positive serum human anti-drug antibody (ADA), or known allergy to any component of ADCT-301
Prior allergy or adverse reaction to methotrexate
Previously identified allergy or hypersensitivity to components of the cabozantinib formulations
Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
No known allergy or adverse reaction (e.g., wound dehiscence) to poly-lactide-co-glycolide (PLG)
History of allergy to mannitol or prior hypersensitivity to thalidomide, lenalidomide or pomalidomide
Previously identified allergy or hypersensitivity to components of the study treatment formulations
Documented allergy to DMSO, mouse or bovine proteins, or iron.
History of allergy to study treatments or any of its components of the study arm that participant is enrolling
Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
Known allergy or reaction to any component of either study drug formulation
Known allergy or hypersensitivity to the components of the atezolizumab formulation.
Known allergy or hypersensitivity to the components of the doxorubicin, cyclophosphamide, carboplatin, or paclitaxel formulations.
Known allergy or hypersensitivity to liposomal or pegylated G-CSF formulations.
Patients with a history of allergy to the study drug components are excluded
Any history of allergy to the study drug components
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy or hypersensitivity to the components of the formulations of atezolizumab, nab-paclitaxel, cyclophosphamide, or doxorubicin, filgrastim or pegfilgrastim
A history of a severe contrast allergy (i.e. anaphylaxis) not controlled with premedication
Known allergy/intolerance to soy, phosphatidylcholine or any other constituents of grape seed extract
Patients with a latex allergy
Known in tolerance and allergy to cytarabine.
The patient has a known allergy/history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab, or any other contraindication to one of the administered treatments
History of allergy to study drug components
Previous known allergy or intolerance to pembrolizumab or any of its excipients
Previous exposure or known allergy to Imprime PGG or any of its excipients
Known allergy or hypersensitivity to any component of the atezolizumab formulation
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
Known allergy to xanthine oxidase inhibitors and/or rasburicase for subjects at risk for tumor lysis syndrome
Known allergy to grapes or grape seed
History of allergy to study drug components
Has had previous exposure to KD025 or known allergy/sensitivity to KD025 or any other ROCK-2 inhibitor.
History of allergy or intolerance to study drug components or polysorbate-80-containing infusions
Have a history of allergy to iodinated contrast media
Allergy to benzamide or inactive components of entinostat.
Known allergy or hypersensitivity to phosphatidylinositol 3 kinase (PI3K) inhibitors or any component of the formulations used in this study.
Known allergy to any of the study medications, their analogues or excipients in the various formulations
Previous history of hypersensitivity to eggs or allergy or untoward reaction to prior vaccinia (smallpox) vaccination
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
DONOR: Known allergy to filgrastim (G-CSF)
Bovine product allergy
Known or suspected allergy or hypersensitivity to the study drug
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Allergy to measles vaccine or history of severe reaction to prior measles vaccination
Allergy to iodine; (NOTE: this does not include reactions to intravenous contrast materials)
Patients with a suspected allergy or sensitivity to any component of MT-3724 drug preparation based upon known allergies to compounds of a similar class who have had an anaphylactic or other severe infusion reaction to human immunoglobulin or monoclonal antibody administration are n ot eligible.
Allergy to shellfish
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
Milk allergy
Allergy or sensitivity to irinotecan or cranberry-grape juice, or any of the irinotecan tablet excipients. .
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known history of contrast allergy that cannot be medically managed
EXCLUSION - TREATMENT: Known allergy to VZV vaccine
Known allergy to any of the study medications, their analogues or excipients in the various formulations
Known allergy to HCQ
History of grade >= 3 allergy to human monoclonal antibodies
Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
Subjects with known allergy or hypersensitivity to any component of the investigational product will be excluded
Patients with known allergy or hypersensitivity to AG120 or venetoclax.
Known allergy to both xanthine oxidase inhibitors and rasburicase
Doxycycline allergy
Allergy or intolerance to roflumilast
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Participants must not have a history of allergy to nivolumab, urelumab or cabiralizumab
Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
History of allergy or hypersensitivity to study drug components
Known allergy or reaction to any component of either study drug formulation
History of gastritis or malabsorption syndrome or aspirin intolerance or allergy
History of allergy to study drug components.
A previously identified allergy or hypersensitivity to components of the study treatment formulation.
Any history of allergy to the study drug components
Known allergy to the study drugs or any of its components
Bupivacaine or liposomal bupivacaine sensitive or known allergy.
Known allergy or hypersensitivity to any of the study drugs or any of their excipients
Any history of allergy to the study drug components
Subjects with an allergy to contrast agents may be enrolled at the treating physician’s discretion with appropriate pre-treatment and symptom management
Known allergy or reaction to any component of either study drug formulation
Known allergy to anthracyclines.
Previously identified allergy or hypersensitivity to any component of the study treatment formulations
Allergy to any component of MSC suspension (such as human albumin) and/or allergy to any drugs used in HCT conditioning regimen
History of allergy to merestinib or chemically related compounds
An allergy or intolerance to egg, gluten or milk protein
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
An allergy to a component of Levulan
History of allergy or intolerance (unacceptable adverse event) to study drugs components.
Subject has known history of allergy, hypersensitivity, or any serious reaction to any of the azole class antifungals.
Has an allergy or hypersensitivity to chili peppers, capsaicin, or radiographic contrast agents.
Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
Patient has a history of allergy to red color food dye or any other component of Qapzola, placebo, or their diluents
Known allergy to both xanthine oxidase inhibitors and rasburicase; or, known hypersensitivity to any of the study drugs
Previously identified allergy or hypersensitivity to components of the study treatment formulations
Allergy to benzamide or inactive components of entinostat
Known allergy or intolerance to any component of belimumab, including human or murine proteins or monoclonal antibodies
Known allergy or hypersensitivity to IP
Allergy or hypersensitivity to components of the cobimetinib formulation
Known allergy to any of the study medications, their analogues or excipients in the various formulations
have a known or suspected allergy to the study drug or any study drug component;
Allergy to carfilzomib or cabozantinib or any excipients
Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty
Has known allergy or reaction to any component of either study drug or formulation components
History of allergy to mouse proteins
History of allergy to study drug components
History of sensitivity or allergy to monoclonal antibodies (mAbs) or immunoglobulin G (IgG)
Known allergy to murine proteins or have had a documented anaphylactic reaction to any drug, or a known hypersensitivity to diphenhydramine or other antihistamines of similar chemical structure.
Known hypersensitivity or allergy to any component of the avelumab formulation
Has a previously identified allergy or hypersensitivity to components of the study treatment formulations
Known allergy or hypersensitivity to intraperitoneal (IP) or any excipient
Allergy to murine-based monoclonal antibodies
Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty
History of allergy to study drug components
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known allergy to grapes or grape seed
Allergy to pembrolizumab or related compounds
Known allergy to nab-paclitaxel or gemcitabine or any ingredient of study drug formulations.
Patients with unconfirmed allergies to piperacillin-tazobactam, cefepime, aztreonam or vancomycin can be evaluated by an allergy/immunology specialist, after which they may become eligible by a consensus of the treating physician, trial investigator and the allergy/immunology specialist
A known allergy or history of hypersensitivity to silicon, phosphorous or any of the OncoSil™ components
Patients with a known allergy to Zometa or to antiemetics appropriate for administration in conjunction with protocol-directed therapy
History of grade 3 or higher allergy to humanized monoclonal antibodies
Known allergy or intolerance to lidocaine
Patients with a known hypersensitivity/allergy to any of the standard of care agents used in this study or related compounds (e.g. platinum compounds) are excluded
Patients with albumin allergy
Gadolinium allergy
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Patients with an allergy, or have experienced any drug reaction to ketamine will be excluded
History of allergy to study drug components
Allergy to benzamide or inactive components of entinostat
Known allergy to coenzyme Q10
Known allergy or adverse reaction to oral, subcutaneous, or intravenous vitamin K
Known allergy or hypersensitivity to any component of the investigational drug product.
Known allergy to doxycycline or tetracycline
History of allergy or adverse drug reaction to study components
Known adverse reactions to heparin (heparin-induced thrombocytopenia or any allergy)
Known allergy or hypersensitivity to investigational product (IP) or any excipient
Known allergy to ODM-201 or any of the excipients.
Known allergy to both xanthine oxidase inhibitors and rasburicase
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
History of allergy to study drug components
History of allergy to components of nivolumab or DS-8273A, or known allergy to other antibody therapies
Known or suspected allergy to lenvatinib or any agent given in the course of this trial
Known allergy to any of the study medications, their analogs, or excipients in the various formulations of any agent
Any known allergy or allergic reactions to Captisol
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent; specifically, prior desquamating rash or erythema nodosum during prior thalidomide or other similar agents
History of severe allergy (e.g., anaphylaxis) to any component of Prevnar or any diphtheria?toxoid containing vaccine
Known allergy or hypersensitivity to study drug formulations
History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.
History of allergy or hypersensitivity to albumin-bound paclitaxel, or gemcitabine
Patients with known allergy to cremophor or polysorbate 80
Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
Known allergy to PIO
Patients may not have any known allergy to CYP and/or GM-CSF.
Allergy to measles vaccine or history of severe reaction to prior measles vaccination
Allergy to iodine; Note: this does not include reactions to intravenous contrast materials
Known allergy to any of the study medications, their analogues or excipients in the various formulations
Allergy to X ray contrast agents.
Severe allergy to contrast agent.
Allergy or hypersensitivity to agents used within the treatment protocol
History of allergy to mouse proteins
Patients who have known allergy to mebendazole
History of sensitivity or allergy to monoclonal antibodies or immunoglobulin G
Known history of allergy or hypersensitivity to study product excipients (human serum albumin, dimethyl sulfoxide [DMSO], and dextran 40)
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent; patient cannot be allergic to boron
Allergy or hypersensitivity to components of the vemurafenib formulation
History of allergy to study drug components
CERITINIB EXCLUSION CRITERIA: Previously identified allergy or hypersensitivity to components of ceritinib formulation
REGORAFENIB EXCLUSION CRITERIA: Previously identified allergy or hypersensitivity to components of regorafenib formulation
ENTRECTINIB EXCLUSION CRITERIA: Previously identified allergy or hypersensitivity to components of entrectinib formulation
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Patient has a history of allergy or intolerance to flucytosine.
Patients with known allergy or hypersensitivity to selinexor, sorafenib or any of its components
Known allergy or hypersensitivity to tetanus, or any other tetanus or diphtheria toxoid-containing vaccine, or any component of this vaccine (i.e., aluminum phosphate, formaldehyde)
Known allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).
Known or suspected allergy or hypersensitivity to regorafenib, or excipients of the formulations given during the course of this trial
Previously identified allergy or hypersensitivity to components of the study treatment formulations
Have known severe intolerance to or life-threatening hypersensitivity reactions to humanized monoclonal antibodies or intravenous immunoglobulin preparations; any history of anaphylaxis; prior history of human anti-human antibody response; known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Patients with known carboplatin or cisplatin allergy
History of allergy to study treatments or any of its components of the study arm that participant is enrolling
History of allergy to study drug components
Known allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product.
Known allergy to sulfa or specific allergy to sulfonylurea drugs
Allergy to gadolinium
Known allergy, hypersensitivity or prior infusion reaction to one or more of the therapies incorporated into this treatment protocol
Patients with a known allergy to cisplatin chemotherapy; patients with carboplatin allergy may be included if they tolerate a test dose of intravenous (IV) cisplatin given in monitored floor conditions
Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty
Known allergy to any of the study medications, their analogues, or excipients in the various formulations
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Patients with known allergy or hypersensitivity to nivolumab, ipilimumab, 5-azacytidine, or any of their components
Allergy to filgrastim, pegfilgrastim, or loratadine
History of allergy to mannitol
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Patients must not have a known history of yeast allergy; if patient has a questionable history of allergy to yeast, a yeast skin test can be performed; patients would be eligible if skin test is negative (note, patients may not be on tricyclic antidepressants at the time of yeast skin test)
Patient does not have known allergy to polyethylene glycol hydrogel (spacer material)
Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty
Known allergy to ixazomib, its analogues, or excipients in the various formulations of ixazomib
Gold allergy
History of allergy or hypersensitivity to nivolumab components
Patients with a known allergy to gadolinium-DTPA
A previously identified allergy or hypersensitivity to components of the study treatment formulation
Known history of allergy to Captisol®
Known or suspected allergy or hypersensitivity to sorafenib
History of allergy to study drug components
Known allergy or reaction to any component of the MEDI4736 formulation or its excipients
Patients with known allergy, intolerance, or resistance (i.e., remission duration less than 6 months or lack of response) to ifosfamide, carboplatin, or etoposide
Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty
Patients with a known allergy to dimethyl sulfoxide (DMSO)
Allergy or hypersensitivity to tetanus vaccine or any component of the tetanus vaccine
Known allergy to fluoropyrimidines or known dihydropyrimidine dehydrogenase (DPD) deficiency.
Patients with a known history of a severe allergy or sensitivity to wheat gluten
MAIN STUDY COHORT EXCLUSION CRITERIA: History of other malignancy with concern for renal metastasis and known allergy to technetium or sestamibi
The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
Subjects with known allergy to lidocaine, epinephrine, itraconazole or petrolatum
History of allergy to mouse proteins
Allergy to measles vaccine or history of severe reaction to prior measles vaccination
Allergy to iodine; this does not include reactions to intravenous contrast materials
The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
Patients with NSAIDs allergies, known lactose allergy, a history of recent gastrointestinal (GI) bleed (less than 2 weeks), and those who are on therapeutic dose anticoagulants will be excluded from this protocol
Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize CFZ), or similar chemical or biologic composition to bendamustine or other agents used in the study
Patients with a known allergy to any component of the study treatment formulations
Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
Must not have any known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).
History of allergy to penicillin or related antibiotic
Patients with known allergy or hypersensitivity to quizartinib, mannitol, AZA, cytarabine or any of their components.
Previously identified allergy or hypersensitivity or intolerance to components of the study treatment formulation (cyclophosphamide, capecitabine, lapatinib [lapatinib ditosylate], trastuzumab)
Patients with an allergy or known hypersensitivity to fish
Known allergy to any of the agents or their ingredients used in this study
Known allergy to sargramostim (GM-CSF)
Patients who are known to have allergy to mouse proteins
Allergy to valacyclovir or unable to take oral tablets
History of allergy to mouse proteins
History of allergy to GM-CSF
Allergy to oseltamivir or excipients
Known allergy to domperidone
Known severe or life-threatening allergy or intolerance to fludarabine, alemtuzumab, cyclosporine, or mycophenolate mofetil.
COHORTS 1 AND 2: HEALTHY VOLUNTEERS: Known allergy or sensitivity to sodium hypochlorite (NaOCl)
Known or suspected allergy to sorafenib, everolimus, or any agent given in the course of this trial
Patients with latex allergy.
Known allergy to any of the study medications, their analogues or excipients in the various formulations
Known allergy to any of the treatment components
History of allergy to mouse proteins
Patients who have an allergy to gold.
Corn allergy
History of allergy to KLH, QS-21, OPT-821, or glucan
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
History of allergy or hypersensitivity to any systemically administered antibody agent or its excipients
Known allergy/hypersensitivity to drug or components
Patients may not have any known allergy to CYP and/or GM-CSF.
History of photosensitizing disease (porphyria, lupus etc.) or of allergy to methylene blue dye.
Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
Patients who have a known history of allergy to Captisol (a cyclodextrin derivative used to stabilize carfilzomib) are NOT eligible for participation
Patients are excluded if there is any history of gadolinium allergy.
Patient having known allergy to NSAID or Aspirin
Known allergy to doxorubicin or anthracyclines.
History of allergy or hypersensitivity to gemcitabine (or other drug excipients in TAR-200) or drugs chemically-related to gemcitabine.
History of allergy or hypersensitivity to the device constituent or Inserter materials.
History of allergy or hypersensitivity to nivolumab drug components.
Known allergy or hypersensitivity to the components of the atezolizumab formulation or to any of the study drugs or excipients, (e.g., Cremophor EL)
Subjects with hypersensitivity or allergy to tetracycline antibiotics or edetate disodium;
History of allergy or hypersensitivity to any of the study drugs.
Known allergy or hypersensitivity to any of the study drugs
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
Patient has a prior allergy or intolerance of ketoconazole
Patient has an allergy or intolerance to sulfites
Patients with known allergy to MB
Previously identified allergy or hypersensitivity to components of the study treatment formulations
Known allergy(ies) to any component of CMB305 or LV305.
Known allergy or hypersensitivity to study treatment or any of the study drugs excipients.
Known allergy, or history of serious adverse reaction to, vaccines such as anaphylaxis, hives, or respiratory difficulty.
History of allergy to or intolerance of ibrutinib or lenalidomide
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Allergy to measles vaccine or history of severe reaction to prior measles vaccination
Known allergy to hyaluronidase
Allergy to brentuximab vedotin and/or nivolumab
History of allergy or hypersensitivity to any of the study drugs or study drug components
Allergy to measles vaccine or history of severe reaction to prior measles vaccination
Allergy to iodine\r\n* Note: This does not include reactions to intravenous contrast materials
Allergy to measles vaccine or history of severe reaction to prior measles vaccination
Dose Escalation cohort only: Allergy to iodine; NOTE: this does not include reactions to intravenous contrast materials
DOSE ESCALATION COHORT: Known allergy or reaction to any component of either study drug formulation; any history of serotonin syndrome (SS) after receiving 1 or more serotonergic drugs
DOSE EXPANSION COHORT: Known allergy or reaction to any component of either study drug formulation; any history of serotonin syndrome (SS) after receiving 1 or more serotonergic drugs
Any history of allergy to the study drug components
History of allergy to study drug components.
Patients with prior allergy to daunorubicin and/or cytarabine
Patients with known allergy to intravenous iodinated contrast agents
Patients who have an allergy/intolerance to sirolimus
The subject has a previously-identified allergy or hypersensitivity to components of the study treatment formulation
DONOR: Known allergy to filgrastim (GCSF)
Allergy to measles vaccine or history of severe reaction to prior measles vaccination
Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
History of allergy or hypersensitivity to any component of the treatment
History of severe environmental allergies or allergy to egg proteins
Allergy to or intolerance of prior doxorubicin-based TACE
Allergy to or intolerance to iodinated contrast media despite standard of care pre-medication
Known or suspected allergy or hypersensitivity to any of the study drug classes
Known allergy to bevacizumab or brentuximab vedotin or any of its excipients
History of allergy to egg proteins
Known history of allergy to Captisol®
Soy allergy
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
History of allergy or untoward reaction to prior vaccination with vaccinia virus
Known allergy or hypersensitivity to azacitidine, mannitol, or midostaurin
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Patients must not have any known allergy or reaction to any component of the nivolumab and ipilimumab formulations
Local or severe allergy to any components of the drug regimen.
History of allergy or hypersensitivity to nab-paclitaxel or carboplatin. 9. Currently enrolled in any other clinical protocol or investigational trial that involved administration of experimental therapy and/or therapeutic devices.
Patient must not have a known allergy to any of the treatment components
Known allergy or hypersensitivity to components of the FPA144 formulation including polysorbate
Known history of positive serum human ADA, or known allergy to any component of ADCT-301.
Known allergy(ies) to any component of CMB305 or CPA
Subject has a history of allergy or hypersensitivity to any study drugs or their excipients.
For the Combination Dose Finding and Combination Expansion cohorts only: previously identified allergy or hypersensitivity to components of the study treatment formulation or panitumumab
Patients with known floxuridine, leucovorin (leucovorin calcium), or mitomycin (mitomycin C) allergy
Known allergy to boron, MLN9708, any of the study treatments, their analogues, or excipients.
History of severe peripheral allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically
Allergy or contraindications to administration of the GI anti-spasmodic drug:
Patients must not have any known allergy or reaction to any component of the MEDI4736 formulation
Subject has a history of allergy or hypersensitivity to study drug components;
Known allergy to both penicillin and sulfa antibiotics
Known allergy to xanthine oxidase inhibitors and/or rasburicase for subjects at risk for TLS
Prior demonstrated hypersensitivity, intolerance or allergy to abiraterone acetate, prednisone or their excipients
No known allergy to platinum compounds
History of allergy to mesothelin-directed antibodies, tubulysin, monoclonal antibodies, nivolumab or related compounds
History of allergy or hypersensitivity to human, humanized or chimeric monoclonal antibodies
Known or suspected allergy to any agent given in the course of this trial
History of severe allergy or intolerance to contrast agents, narcotics sedatives or atropine that cannot be managed medically
Known allergy to latex or gadolinium (Gd).
Known allergy or hypersensitivity to any component of the atezolizumab formulation
Known allergy or hypersensitivity to any component of the bevacizumab formulation
have a known allergy or hypersensitivity reaction to any of the treatment components
Have a known allergy or hypersensitivity reaction to any of the treatment components.
Allergy to ciprofloxacin (or other quinolones), acetylsalicylic acid, or indomethacin.
Known allergy, or history of serious adverse reaction to, vaccines such as anaphylaxis, hives, or respiratory difficulty
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial.
Patients with known allergy or hypersensitivity to lirilumab, 5-azacytidine, or any of their components; patients who have previously been treated with lirilumab in combination with 5-azacytidine will be excluded
Have a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab, or any other contraindication to one of the administered treatments.
Known allergy to iron dextran or presence of human anti-mouse antibodies
Have known allergy or hypersensitivity to any components of study treatment.
History of allergy to murine proteins
History of allergy or hypersensitivity to study product excipients (human serum albumin, dimethyl sulfoxide [DMSO], and Dextran 40)
A history of allergy to human monoclonal antibodies.
Patients with known allergy to sorafenib or azacitidine, mannitol or any of their components
Known or suspected allergy to sorafenib or any agent given in the course of this trial
Known allergy(ies) to any component of the study agent GLA-SE including egg lecithin
History of allergy to murine proteins
History of allergy or hypersensitivity to study product excipients (human serum albumin, dimethyl sulfoxide [DMSO], and Dextran 40)
Have a known allergy to tomatoes or have never consumed tomatoes
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
History of allergy to components of ipilimumab or panobinostat, or known allergy to other antibody therapies
Known allergy to thalidomide.
Patients must not have a known allergy to mannitol
The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
Subject has a known allergy to ART-123 or any components of the drug product.
Allergy to ganciclovir or acyclovir
History of allergy to mouse proteins
Subjects with known allergy or hypersensitivity to any component of the investigational product will be excluded
Known allergy to both xanthine oxidase inhibitors and rasburicase
Allergies and Adverse Drug Reaction: History of allergy to study drug components
History of allergy to study drug components
Has known or suspected allergy or sensitivity to any test materials, reagents, or WCE contrast materials
Subject has a known sensitivity or allergy to bovine and/or porcine substance(s) or any other component(s) of the hemostatic agent;
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy to both penicillin and trimethoprim/sulfamethoxazole. Participants who are allergic to only one of these antibiotics are allowed to enroll
Known allergy or hypersensitivity to IP formulations or to other human monoclonal antibodies
Patient has a history of allergy to red color food dye.
A known allergy to any component of LY2157299.
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
History of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
Known allergy to hyaluronidase
The participant has a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab or pembrolizumab, or any other contraindication to one of the administered treatments.
Allergy to meclofenamate or other nonsteroidal antiinflammatory drug (NSAID)
History of allergy or intolerance (unacceptable adverse event) to study drugs components
Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
Previously identified allergy or hypersensitivity to components of the study treatment formulations
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known allergy or hypersensitivity to paclitaxel or any components used in the paclitaxel preparation or other contraindication for taxane therapy
Known allergy to any of the vaccine or adjuvant components, including eggs
Known allergy or hypersensitivity to Investigational Product.
Patients with documented allergy to cephalosporins
Patients may not have a known allergy or hypersensitivity to any of the components of the investigational therapy, including polyethylene glycol (PEG) or topoisomerase inhibitors
Has allergy to enzalutamide
Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
Patient has a known allergy to both penicillin and sulfa
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
All patients who have received prior vaccination with vaccinia virus (for smallpox immunization) must not have a history of allergy to the vaccine
Patients with known allergy to eggs
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
Known or suspected allergy to sorafenib or any agent given in the course of this trial
Known history of allergy to Captisol
No known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
Known allergy to both xanthine oxidase inhibitors and rasburicase
Allergy or hypersensitivity to components of the cobimetinib formulations
Patients who have a history of allergy to iodides or iodinated contrast agents
Patients with a known allergy to murine proteins or have had a documented anaphylactic reaction or allergy to any of chemotherapy agents used in this protocol, oregovomab, or to antiemetics appropriate for administration in conjunction with protocol-directed therapy
Known allergy to any of the drugs used in the study. (Subjects who have had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible.)
Known allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
Known allergy attributed to bupropion, varenicline, transdermal or lozenge nicotine
An allergy to iodine
Known allergy or adverse drug reaction to nivolumab, or a history of allergy to study drug components
Known or suspected allergy to gemcitabine or MLN8237, or any agent given in the course of this trial
Known or suspected allergy to irinotecan or MLN8237, or any agent given in the course of this trial
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
History of allergy or hypersensitivity to any component of the study drugs
Known allergy to any of the study medications
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
A known history of allergy or hypersensitivity to any of the study drugs or any of their excipients.
The patient has a previously-identified allergy or hypersensitivity to components of the study treatment formulation
Known or suspected allergy to gemcitabine or cisplatin
History of allergy to mannitol
A known allergy to any component of the HyperAcute®-Lung immunotherapy or cell lines from which it is derived.
Known allergy to any of the treatment components
Known allergy to bortezomib, boron, or mannitol
Patients who have known allergy to mebendazole or benzimidazole
Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)
Known allergy to any of the study medications, their analogues, or excipients in the various formulations
The patient has known allergy to any of the treatment components
Allergy or hypersensitivity to agents used within the treatment protocol
Known allergy to any of the compounds under investigation
Have a known allergy to resiquimod or any of the excipients in the study drug
Known or suspected allergy or hypersensitivity to yeast or any other component of CRS-207 (e.g., glycerol), Platinol or platinum-containing compounds, or pemetrexed
The subject has a previously-identified allergy or hypersensitivity to components of the study treatment formulation
Medically diagnosed lactose intolerance, lactose allergy or salicylate allergy
The participant has a previously identified allergy or hypersensitivity to components of the study treatment formulation
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
If patients meet any of the following they will be excluded:\r\n* Active infection requiring intravenous treatment or having an unexplained febrile illness (temperature maximum [Tmax] > 99.5 Fahrenheit [F]/37.5 Celsius [C])\r\n* Known immunosuppressive disease or known human immunodeficiency virus infection\r\n* Unstable or severe intercurrent medical conditions such as severe heart (New York Heart Association class 3 or 4) or known lung (forced expiratory volume in 1 second [FEV1] < 50%) disease, uncontrolled diabetes mellitus\r\n* Albumin allergy; patients with a known allergy will be excluded\r\n* Gadolinium allergy
Known allergy to any of the study medications, their analogues or excipients in the various formulations
History of known allergy or contraindications to the use of pazopanib, paclitaxel, or carboplatin
Known allergy to gadolinium
Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
Known or suspected allergy to pazopanib
18F FLT CANDIDATE TRANSPLANT RECIPIENT: History of prior fluorothymidine allergy or intolerance
Subjects with known allergy or hypersensitivity to doxorubicin, cyclophosphamide, or eribulin mesylate.
History of allergy to platinum compounds or to antiemetics appropriate for administration in conjunction with protocol-directed chemotherapy
Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).
Patient has a known allergy to any component of the study treatment formulations
Allergy to valproic acid
Known or suspected allergy to ARQ 197
Allergy to benzamide or inactive components of entinostat
History of allergy to study drug components
Previously identified allergy or hypersensitivity to components of the study treatment formulations.
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Patients with a history of allergy to entinostat or other medications that have a benzamide structure (i.e. tiapride, remoxipride, and clebopride)
History of allergy or reaction to any component of the MEDI-551 formulation
Known allergy to allopurinol for subjects assessed with PR following their second-line induction therapy.
Patients with a known allergy to any component of vorinostat, or a known allergy to temozolomide and/or isotretinoin.
Known or suspected allergy to sorafenib (BAY 43-9006) or any agent given in association with this trial
Patients with known allergy to etoposide or a history of grade 3 hemorrhagic cystitis with cyclophosphamide are not eligible
DONOR: Known allergy to filgrastim (G-CSF)
DONOR: Known allergy to G-CSF
Patients will be excluded if they have a known allergy to any of the drugs used in the study
History of severe allergy to any of the components of NEOD001 such as histidine/L-Histidine, Trehalose, or Polysorbate 20
Has known allergy or history of adverse reaction to ICG, iodine or iodine dyes.
Allergy to measles vaccine or history of severe reaction to prior measles vaccination.
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial.
Known allergy to bone cement,
Patients will be excluded if they have a known allergy to any of the drugs used in the study.
Any known allergy to the compounds under investigation
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Patients with known allergy or hypersensitivity to IMGN901
Known allergy to wheat, rice (contained in the placebo), orange or the sweetener, Stevis
A known history of allergy or hypersensitivity to any of the study drugs or any of their excipients.
Known allergy to hyaluronidase or any constituents of docetaxel formulation.
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Subject has a history of allergy or hypersensitivity to nab-paclitaxel or gemcitabine or any of their excipients.
Known or suspected grade 3 allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Bovine product allergy
Known allergy to any of the study drugs
Known allergy to BCG or MMC
Known or suspected grade 3 allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy or hypersensitivity to any of the formulation components
Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Prior history of penicillin or streptomycin allergy
Known intolerance or allergy to MR contrast agent (gadolinium chelates) including advanced kidney disease
Patients with a soy allergy will be excluded
Known allergy or hypersensitivity to any component of the study treatment(s)
History of severe allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically
Known or suspected allergy to the investigational agents or any agent given in association with this trial (hypersensitivity reaction, hives, rash, difficulty breathing swelling of your face, lips, tongue, or throat)
Patient has a history of allergy or hypersensitivity to the study drugs
History of hypersensitivity or allergy to study drugs, aspirin, sulfonamides, or NSAIDs
The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
The subject has a known allergy to tetracycline
Patient has a history of allergy or hypersensitivity to the study drugs
Known allergy to macrolide antibiotics
Known allergy to eggs, gentamicin or platinum-containing compounds
Known allergy to any of the study agents
History of allergy to nivolumab components
Allergy to either of the study medications or 5-fluorouracil
Nut allergy
Subject has a previously-identified allergy or hypersensitivity to components of the study treatment formulation
Allergy or hypersensitivity to components of either study drug formulation
Known allergy to any study drug or ingredient contained in the drug formulation of any of the study drugs.
Allergy or hypersensitivity to components of the cobimetinib or GDC-0994 formulation
Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)
Known allergy or history of adverse reaction to ICG, iodine or iodine dyes.
Known allergy or history of adverse reaction to Blue dye (Isosulfan blue) or triphenylmethane.
Known allergy to paclitaxel or any of its components
History of Grade ? 3 allergy to human monoclonal antibodies.
Known allergy to any of the components used during vertebroplasty (polymethyl methacrylate [PMMA] bone cement)
Allergy to implant materials or dental glue.
Patients with known sensitivity or allergy to any components of AMP-224
History of severe environmental allergies or allergy to egg proteins
Known allergy to any of the study drugs or their excipients.
Patient who has a history of allergy or hypersensitivity to any of the study drugs
Known hypersensitivity/allergy to fluconazole or itraconazole or their respective excipients.
Allergy or hypersensitivity to components of the cobimetinib formulations
Does the subject have a history of allergy or intolerance to flucytosine?
The patient has a previously-identified allergy or hypersensitivity to components of the study treatment formulations.
Subjects with a known history of allergy to paclitaxel. Subjects whose allergy was due to the IV solvent (such as Cremophor®) and not paclitaxel will be eligible for this study.
Known allergy to treatment medication (vemurafenib)
The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
Known allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product.
Known allergy to study medications
History of significant drug-related allergy (such as anaphylaxis)
Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
Patients with known allergy/hypersensitivity to warfarin or bupropion and/or related compounds
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
Known allergy or hypersensitivity to any component of the formulation of CA-4948 used in this study
Known allergy to doxycycline or other tetracycline antibiotics
Allergy to mannitol
Known history of allergy to Captisol(a cyclodextrin derivative used to solubilize carfilzomib).
Known or suspected allergy or hypersensitivity to any component of TH-302, sorafenib, or any of the sorafenib excipients
History of allergy to Urelumab (BMS-663513) or related compounds
History of significant drug allergy (such as anaphylaxis or hepatotoxicity) to a prior biologic therapy
Known or suspected hypersensitivity to any component of GVAX Pancreas vaccine or CRS-207, or known allergy to both penicillin and sulfa
Known allergy to any of the study medications
Known or suspected allergy to sorafenib
The patient has a known allergy/history of hypersensitivity reaction to any of the treatment components.
Known or suspected allergy to sorafenib or any agent given in the course of this trial
Allergy / history of hypersensitivity reaction to any of the treatment components
allergy or intolerance to 5-FC
Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)
Subject has known sensitivity or allergy to heparin
Known or suspected allergy to any agent given in the course of this trial
History of allergy or hypersensitivity to nab-paclitaxel, albumin or a taxane
Allergy: known hypersensitivity to other recombinant human antibodies
Known allergy to eggs
Known severe or life-threatening allergy or intolerance to ATG or cyclosporine/ tacrolimus
History of allergy to study drug components
Patients with known allergy or hypersensitivity to ponatinib, or 5-azacytidine, or any of their components
Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugs
Allergy to gadolinium
Allergy or hypersensitivity to components of the vemurafenib formulation
Known allergy to any of the agents or their ingredients used in this study
Allergy to bupropion
Known allergy to adhesive tape
Known allergy to EACA
Allergy to allopurinol
known allergy to both penicillin and sulfa drugs
Is known or suspected to have an allergy to opioids, muscle relaxants or other medications used during general anesthesia
Allergy to egg or egg byproducts
Women with dialysis, chronic urinary infection, hyperthyroidism, current infection, or a history of allergy or sensitivity to iodine will not be eligible to participate
Known history of allergy or intolerance to montelukast, zafirleukast, azithromycin, erythromycin, clarithromycin, prednisone, or sirolimus
Allergy to botulinum toxin, and or egg
Known sensitivity or allergy to fish or fish oil
Fish and/or fish oil allergy or intolerance
Milk allergy excluding lactose intolerance
Allergy or intolerance to bupivacaine or “amide” anesthetics
Known allergy to soy or any soy-based food or supplement
Known allergy to local anesthetics
Known allergy to perampanel
Known allergy to or prior intolerance of aspirin and/or simvastatin
History of an allergy to romiplostim
Patients with known sensitivity or allergy to porcine materials
Known allergy to the standard of care or ingredients in KeraStat Cream
History of allergy to fentanyl
Allergy treatment with antigen injections
Allergy or adverse reaction to local anesthesia catheter
Known true tape allergy
No known allergy to ingredients of banana bread preparation (eggs, almonds and other nuts since the celery also has almond powder)
Known allergy to stevia
History of known allergy to components of the study supplements
Allergy or intolerance to 5HT3 or NK-1 antagonists and dexamethasone
Allergy treatment with antigens injections
Patients with a known allergy or hypersensitivity to CHG are ineligible
Patients with an allergy to quinolones
Patients must have no known allergy or hypersensitivity to duloxetine or any of the inactive ingredients in the matching placebo
Known allergy to a probiotic preparation
Food allergy to any component of the supplement
History of allergy to investigational agent: ropivacaine or other amino amide analgesics
History of allergy to standard agent: propofol
Allergy to fentanyl
Allergy to gabapentin
No known allergy to diphenhydramine, lidocaine, antacid (aluminum hydroxide, magnesium hydroxide, and simethicone), doxepin, tricyclic antidepressants, or any known component of the drug formulation in the testing arms
Antibiotic allergy to study medication
Allergy to bone morphogenetic protein
Known allergy to both penicillin and trimethoprim/sulfamethoxazole. Participants who are allergic to only one of these antibiotics are allowed to enroll
Known allergy to any of the treatment components.
Allergy or hypersensitivity to components of the emactuzumab formulation or to components of the atezolizumab formulation
Arm C: Patients with a methotrexate allergy are excluded
Previous intolerance/adverse effect/allergy to any component of the placebo or active agent
Allergy to beef
History of allergy to fentanyl
History of allergy to fentanyl
Participant has a known allergy to melatonin or any ingredients of the study product or placebo
Patients with a history of skin allergy to iodine or adhesive drapes
Patients must not have an allergy to latex
Patients with history of allergy or adverse reactions to sodium bicarbonate or normal saline
No known allergy to either ACE inhibitors or ?-blockers
Known allergy to phenylephrine
Doxycycline allergy
Allergy to sugar substitute
Allergy to gabapentin
Have sensitivity or allergy to fish and/or shellfish
Have sensitivity or allergy to soy and/or soybeans
Allergy to either Eucerin or MF
Known allergy or preexisting skin disease which prohibits use of menthol
Patients with a history of allergy or adverse reaction to corticosteroids
Prior history of (H/O) severe allergy or asthma requiring active treatment
Patients with a history of allergy to human proteins
Known allergy to a probiotic preparation
Allergy or prior reaction to the fluorescent contrast agent proflavine
Allergy or intolerance to gadolinium
Allergy or prior reaction to the fluorescent contrast agent proflavine
Participants who have a known allergy to contrast media.
Participants who have a known allergy to contrast media
History of allergy to acetic acid
History of allergy to apixaban or Factor Xa inhibitors
History of any significant drug allergy (such as anaphylaxis or hepatotoxicity
Documented allergy to iron dextran or murine proteins
Allergy to any component of the HPV vaccine including yeast and aluminum
Known allergy to electrode adhesives or woven knit compression fabrics
RECIPIENT: Allergy treatment with antigens injections
Have known hypersensitivity or allergy to eggs, egg or chicken protein, or other components of the study vaccine
Known allergy to LCM or LEV
Known history of allergy to any component or other contraindications to any Neurokinin-1 (NK1) or 5-hydroxytryptamine 3 (5-HT3) receptor antagonists.
Individuals with a known allergy to lidocaine are not eligible
History of allergy or intolerance to ISA
Patients with known allergy to boron or boron-containing products, or excipients in the various formulations of any agent
Women with a known allergy to proflavine, acriflavine, or iodine
Women with an allergy to rapamycin or its derivatives
Any known allergy or hypersensitivity to vaginal lubricants or any component of study product
Documented allergy to apixaban and/or enoxaparin
Allergy to nicotine patch, nicotine lozenge, or varenicline
Known sensitivity or allergy to fish
Patient has allergy to fish or is a vegetarian
Patients who have an allergy to eggs
Known allergy to any of the components of ATIR101 (e.g., dimethyl sulfoxide)
Known allergy to any of the components of ATIR101 (e.g., dimethyl sulfoxide)
Known sensitivity or allergy to turmeric spices or curry
Bovine product allergy.
Subjects with a known allergy to lidocaine
Patients with an allergy to Peridex/chlorhexidine solution
Any serious egg allergy or prior serious adverse reaction to an influenza vaccine
Has a history of significant allergy to calcitriol as determined by the investigator.
Allergy to yeast or any of the components of Gardasil
Has known allergy to Tc99m sestamibi
Iodide or seafood allergy
History of allergy to any of the components of OTL38, including folic acid
History of allergy or hypersensitivity to any component of the treatment
Women with a known allergy to proflavine or acriflavine
Subjects with known hypersensitivity and allergy to iron
Known allergy to adhesive tapes or other skin adhesives used in medical care
Known prior allergic reaction to ICG or allergy to iodine
Allergy to sulfa or sulfa-containing medications
Allergy to sulfa or sulfa-containing medications
History of allergy to iodide drugs or shellfish (iodine allergy)
Any known allergy or prior reaction to fluorescein
Prior history of hypersensitivity to pegylated liposomal doxorubicin or indocyanine green (ICG) allergy; caution should be taken if prior ICG allergy is noted
Women with iodine contrast allergy
Women with gadolinium contrast allergy
Subjects with contraindications to the use of [18F] FAZA including confirmed allergy.
Subject has an allergy against iodinated contrast agents and cannot be premedicated
Allergy to gadolinium containing contrast media
History of iodinated contrast allergy
Known allergy to FDG or gadolinium based contrast agents
Any known allergy or prior reaction to fluorescein, iodine, or shellfish
Patients with a known allergy to Benadryl
Patients with a known allergy or hypersensitivity to MRI contrast agents including gadolinium
Known allergy to gadolinium or the sedative, propofol, used during MRI
Subjects with established allergy to IV GBCA
Patients with history of allergy to hydrogel dressing or ongoing skin diseases
History of serious allergy or reaction to any component of RICE or RDHAP formulations that would prevent administration
Patients with a known allergy to MR contrast agents
Has known allergy to Tc 99m sestamibi
Participants who have a known allergy to contrast media
History of prior fluorothymidine allergy or intolerance
Women with a known allergy to proflavine or acriflavine
Patients with allergy to regadenoson
Known allergy to iodine or intravenous contrast agent.
Known allergy or anaphylactic reaction to indocyanine green (ICG).
Previous intravenous (IV) contrast allergy
Severe food or medication allergy
Allergy to gadolinium or other severe drug allergies
Known allergy to proflavine or acriflavine
Patient with allergy to contrast agent
History of allergy to iodine
History of multiple food and/or drug allergy
Has a known allergy to dextran or VBD (if intended to be used)
Known allergy to gadolinium.
Patients with known hypersensitivity or allergy to any component of Sonazoid.
No allergy to gadolinium
Patients with known hypersensitivity or allergy to any component of Definity
Any known allergy or prior reaction to fluorescein; also, a positive skin prick test to fluorescein is considered an exclusion criteria and the patient would not be eligible for entry into this study
History of any anaphylactic reaction, any severe allergy, or any allergy to folate
Patients with allergy to iodinated contrast
Subjects who have a known allergy to iron
History of clinically significant sensitivity or allergy to monoclonal antibodies, their excipients, or intravenous gamma globulin
Allergy to fluorescein
Allergy to CT contrast media requiring the administration of steroid prophylaxis
Allergy to intravenous CT contrast media
Has a known allergy to dextran
Known allergy to gadolinium containing contrast agents
Known allergy to FdCyd
Subjects with known hypersensitivity and allergy to gadolinium contrast agents
Documented or reported contrast allergy
Have a known allergy to iodinated contrast agent
NORMAL VOLUNTEERS: Have a known allergy to iodinated contrast agent
Iodine allergy, hyperthyroidism, or Grave’s disease
The patient has a documented intravenous contrast allergy or iodine allergy
Patient must not have a history of allergy or bronchial asthma
Allergy to fluoroquinolones
Allergy to any component of sipuleucel-T
Allergy to Brussels sprouts
Participants with a known or suspected allergy to iodine
Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Known allergy or hypersensitivity to monoclonal antibodies
Participants with aspirin or other NSAIDs-induced asthma or hypersensitivity reaction, sulfonamide allergy
No known sensitivity or allergy to nonsteroidal anti-inflammatory drugs (NSAIDs)
Nut or seed allergy
No known allergy to tree nuts
History of allergy to any of the components of OTL38, including folic acid
Allergy or hypersensitivity to components of the GDC-0994 formulation
Has a known history of hypersensitivity or allergy to pembrolizumab and any of its components and/or to any of the study chemotherapies (e.g., nab-paclitaxel, paclitaxel, gemcitabine, or carboplatin) and any of their components.
Participant must not have a history of allergy to erlotinib
